Review Article - Botulinum toxins: Pharmacology and its current therapeutic evidence for use
Botulinum toxins are, as a group, among the most potent neuromuscular toxins known, yet they are clinically useful in the management of conditions associated with muscular and glandular over-activity. Botulinum toxins act by preventing release of acetylcholine into the neuromuscular junction. While...
Gespeichert in:
Veröffentlicht in: | Neurology India 2003-12, Vol.51 (4) |
---|---|
1. Verfasser: | |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | |
---|---|
container_issue | 4 |
container_start_page | |
container_title | Neurology India |
container_volume | 51 |
creator | Muthane U, Panikar D |
description | Botulinum toxins are, as a group, among the most potent neuromuscular
toxins known, yet they are clinically useful in the management of
conditions associated with muscular and glandular over-activity.
Botulinum toxins act by preventing release of acetylcholine into the
neuromuscular junction. While botulinum toxin type A is commonly
available, different manufacturers produce specific products, which are
not directly interchangeable and should not be considered as
generically equivalent formulations. Type B is also available in the
market. Each formulation of botulinum toxin is unique with distinct
dosing, efficacy and safety profiles for each use to which it is
applied. Botulinum toxin type A is the treatment of choice based on its
depth of evidence in dystonias and most other conditions. Botulinum
toxin type A is established as useful in the management of spasticity,
tremors, headache prophylaxis and several other neurological
conditions. Active research is underway to determine the parameters for
which the type B toxin can be used in these conditions, as covered in
this review. Botulinum toxin use has spread to several fields of
medicine. |
format | Article |
fullrecord | <record><control><sourceid>bioline</sourceid><recordid>TN_cdi_bioline_primary_cria_bioline_ni_ni03150</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>cria_bioline_ni_ni03150</sourcerecordid><originalsourceid>FETCH-bioline_primary_cria_bioline_ni_ni031503</originalsourceid><addsrcrecordid>eNqVjc0KwjAQhHNQ8Pcd9gUqrUEp3lQUjyIehRLTVVfSRDaJ2rc3B30AYWCYgW-mI_p5Pi0zWZbznhh4f09RymLaF6cDPglfsORA2iBksHIhGrKxgeDeZP0C9jfFjdLOuGsLytZAwYOOzGgDhBuyemBMOKSpGq1GuDiG6HEkuhdlPI6_PhST7ea43mVncukCqwdTo7itNJOqfqWlpFwWs1z-DXwA-RJNcw</addsrcrecordid><sourcetype>Publisher</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Review Article - Botulinum toxins: Pharmacology and its current therapeutic evidence for use</title><source>Bioline International</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><creator>Muthane U, Panikar D</creator><creatorcontrib>Muthane U, Panikar D</creatorcontrib><description>Botulinum toxins are, as a group, among the most potent neuromuscular
toxins known, yet they are clinically useful in the management of
conditions associated with muscular and glandular over-activity.
Botulinum toxins act by preventing release of acetylcholine into the
neuromuscular junction. While botulinum toxin type A is commonly
available, different manufacturers produce specific products, which are
not directly interchangeable and should not be considered as
generically equivalent formulations. Type B is also available in the
market. Each formulation of botulinum toxin is unique with distinct
dosing, efficacy and safety profiles for each use to which it is
applied. Botulinum toxin type A is the treatment of choice based on its
depth of evidence in dystonias and most other conditions. Botulinum
toxin type A is established as useful in the management of spasticity,
tremors, headache prophylaxis and several other neurological
conditions. Active research is underway to determine the parameters for
which the type B toxin can be used in these conditions, as covered in
this review. Botulinum toxin use has spread to several fields of
medicine.</description><identifier>ISSN: 0028-3886</identifier><language>eng</language><publisher>Medknow Publications on behalf of the Neurological Society of India</publisher><subject>Botulinum toxin, Serotypes, Formulations, Review, Dystonia, Hemifacial spasms, Tremors, Migraine, Tics, Spasticity, Antibody-mediated resistance, Endopeptidase</subject><ispartof>Neurology India, 2003-12, Vol.51 (4)</ispartof><rights>Copyright 2003 Neurology India. Online full text also at http://www.neurologyindia.com/article.asp?issn=0028-3886;year=2003;volume=51;issue=4;spage=455;epage=460;aulast=Muthane</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,79169</link.rule.ids></links><search><creatorcontrib>Muthane U, Panikar D</creatorcontrib><title>Review Article - Botulinum toxins: Pharmacology and its current therapeutic evidence for use</title><title>Neurology India</title><description>Botulinum toxins are, as a group, among the most potent neuromuscular
toxins known, yet they are clinically useful in the management of
conditions associated with muscular and glandular over-activity.
Botulinum toxins act by preventing release of acetylcholine into the
neuromuscular junction. While botulinum toxin type A is commonly
available, different manufacturers produce specific products, which are
not directly interchangeable and should not be considered as
generically equivalent formulations. Type B is also available in the
market. Each formulation of botulinum toxin is unique with distinct
dosing, efficacy and safety profiles for each use to which it is
applied. Botulinum toxin type A is the treatment of choice based on its
depth of evidence in dystonias and most other conditions. Botulinum
toxin type A is established as useful in the management of spasticity,
tremors, headache prophylaxis and several other neurological
conditions. Active research is underway to determine the parameters for
which the type B toxin can be used in these conditions, as covered in
this review. Botulinum toxin use has spread to several fields of
medicine.</description><subject>Botulinum toxin, Serotypes, Formulations, Review, Dystonia, Hemifacial spasms, Tremors, Migraine, Tics, Spasticity, Antibody-mediated resistance, Endopeptidase</subject><issn>0028-3886</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2003</creationdate><recordtype>article</recordtype><sourceid>RBI</sourceid><recordid>eNqVjc0KwjAQhHNQ8Pcd9gUqrUEp3lQUjyIehRLTVVfSRDaJ2rc3B30AYWCYgW-mI_p5Pi0zWZbznhh4f09RymLaF6cDPglfsORA2iBksHIhGrKxgeDeZP0C9jfFjdLOuGsLytZAwYOOzGgDhBuyemBMOKSpGq1GuDiG6HEkuhdlPI6_PhST7ea43mVncukCqwdTo7itNJOqfqWlpFwWs1z-DXwA-RJNcw</recordid><startdate>20031231</startdate><enddate>20031231</enddate><creator>Muthane U, Panikar D</creator><general>Medknow Publications on behalf of the Neurological Society of India</general><scope>RBI</scope></search><sort><creationdate>20031231</creationdate><title>Review Article - Botulinum toxins: Pharmacology and its current therapeutic evidence for use</title><author>Muthane U, Panikar D</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-bioline_primary_cria_bioline_ni_ni031503</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2003</creationdate><topic>Botulinum toxin, Serotypes, Formulations, Review, Dystonia, Hemifacial spasms, Tremors, Migraine, Tics, Spasticity, Antibody-mediated resistance, Endopeptidase</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Muthane U, Panikar D</creatorcontrib><collection>Bioline International</collection><jtitle>Neurology India</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Muthane U, Panikar D</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Review Article - Botulinum toxins: Pharmacology and its current therapeutic evidence for use</atitle><jtitle>Neurology India</jtitle><date>2003-12-31</date><risdate>2003</risdate><volume>51</volume><issue>4</issue><issn>0028-3886</issn><abstract>Botulinum toxins are, as a group, among the most potent neuromuscular
toxins known, yet they are clinically useful in the management of
conditions associated with muscular and glandular over-activity.
Botulinum toxins act by preventing release of acetylcholine into the
neuromuscular junction. While botulinum toxin type A is commonly
available, different manufacturers produce specific products, which are
not directly interchangeable and should not be considered as
generically equivalent formulations. Type B is also available in the
market. Each formulation of botulinum toxin is unique with distinct
dosing, efficacy and safety profiles for each use to which it is
applied. Botulinum toxin type A is the treatment of choice based on its
depth of evidence in dystonias and most other conditions. Botulinum
toxin type A is established as useful in the management of spasticity,
tremors, headache prophylaxis and several other neurological
conditions. Active research is underway to determine the parameters for
which the type B toxin can be used in these conditions, as covered in
this review. Botulinum toxin use has spread to several fields of
medicine.</abstract><pub>Medknow Publications on behalf of the Neurological Society of India</pub></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0028-3886 |
ispartof | Neurology India, 2003-12, Vol.51 (4) |
issn | 0028-3886 |
language | eng |
recordid | cdi_bioline_primary_cria_bioline_ni_ni03150 |
source | Bioline International; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals |
subjects | Botulinum toxin, Serotypes, Formulations, Review, Dystonia, Hemifacial spasms, Tremors, Migraine, Tics, Spasticity, Antibody-mediated resistance, Endopeptidase |
title | Review Article - Botulinum toxins: Pharmacology and its current therapeutic evidence for use |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-28T16%3A08%3A35IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-bioline&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Review%20Article%20-%20Botulinum%20toxins:%20Pharmacology%20and%20its%20current%20therapeutic%20evidence%20for%20use&rft.jtitle=Neurology%20India&rft.au=Muthane%20U,%20Panikar%20D&rft.date=2003-12-31&rft.volume=51&rft.issue=4&rft.issn=0028-3886&rft_id=info:doi/&rft_dat=%3Cbioline%3Ecria_bioline_ni_ni03150%3C/bioline%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/&rfr_iscdi=true |